Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Hormonal Therapy Gene Profiles in Breast Cancer
NCT04129216Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamoxifen, letrozole and exemestane in breast cancer (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Change in Percent Expression of Ki67 up to 6 weeks. Started Feb 2019; status: completed.
02
Drugs
tamoxifenletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04129216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129216.